It was great to talk with Dr Lianne Kearsley-Fleet (Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK) around her study on ‘Real-world effectiveness of etanercept and adalimumab in children and young people with juvenile idiopathic arthritis (JIA) without uveitis.‘ (POS1292), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What questions remain unanswered in the clinical utility of TNF inhibitors in children and young people with juvenile idiopathic arthritis without uveitis? (0:25)
- What were the objectives and design of your study? (1:35)
- What were the study findings in terms of the comparative effectiveness of adalimumab and etanercept? (2:29)
- How will these findings impact on clinical practice? (2:54)
Disclosures: Lianne Kearsley-Fleet has nothing to disclose in relation to this video.
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
